John Fuller

Biochemistry, Genetics and Molecular Biology · Life Sciences

57h-index15.2kcitations203works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(32), Diabetes, Cardiovascular Risks, and Lipoproteins(31), Diabetes Treatment and Management(26), Diabetes Management and Research(25), Cardiovascular Function and Risk Factors(22)

Publications203 total

Unseen Risks: How AI chatbots threaten vulnerable youth
Mental Health Weekly·2025
Supervisory control and data acquisition for localized grids in extended reality
World Journal of Advanced Engineering Technology and Sciences·2025Open Access
Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study
Diabetologia·2023· 40 citedOpen Access
Introduction to Power Protection Systems
2023
Transformer Protection
2023· 1 cited
Overcurrent Relay
2023
Fuses and Circuit Breakers
2023
Grounding of Power System
2023· 1 cited
Faults Analysis
2023
Protective Relays
2023
Generator, Motor, and Busbar Protection
2023
Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes
Journal of Medicinal Chemistry·2023· 3 citedOpen Access
Table S6 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
2023Open Access
Table S4 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
2023Open Access
Table S4 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
2023Open Access
Table S2 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
2023Open Access
Table S8 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
2023Open Access
Table S9 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
2023Open Access
Table S3 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
2023Open Access
Figure S2 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Nish Chaturvedi(24), Helen M. Colhoun(11), Coen D.A. Stehouwer(9), D. J. Betteridge(8), Paul N. Durrington(7), G. A. Hitman(7), Casper G. Schalkwijk(7), Shona Livingstone(6), David A. DeMicco(6), H. A. W. Neil(5), Valentine Charlton-Menys(5), Daniel R. Witte(5), Massimo Porta(5), Anne Katrin Sjølie(4), Sabita S. Soedamah‐Muthu(4), Lynda Stevens(4), Miranda T. Schram(4), Solomon Tesfaye(3), Ronald Klein(3), Trevor J. Orchard(3)